Cancer Gene Therapy Market By Therapy Type (Gene Insertion {Suicide Gene Therapy, Tumor Suppressor Gene Therapy}, Gene Modification {Oncolytic Virotherapy, Antisense and RNAi}, Immunotherapy Based Gene Therapy, Others), By Indication (Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer, Lung Cancer, Prostate Cancer, Others), By End-user (Hospitals, Oncology Institutes, Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Cancer Gene Therapy Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising prevalence of cancer globally fuels demand for advanced treatments

3.2.2. Technological advancements in gene editing and CAR-T therapies drive innovation

3.2.3. Increasing investments in biotechnology and research accelerate market growth

3.3. Key industry pitfalls & challenges

3.3.1. The high cost of gene therapy treatments limits accessibility for many patients

3.3.2. Regulatory challenges and lengthy approval processes hinder product commercialization

3.3.3. Potential safety concerns and side effects associated with gene therapy limit adoption

3.4. Market Opportunities

3.4.1. Expanding healthcare access in emerging markets presents growth potential

3.4.2. Collaborations and partnerships among biotech firms foster innovation in gene therapy

3.4.3. Advancements in personalized medicine create tailored treatments for cancer patients

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Cancer Gene Therapy Market, Therapy Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Gene Insertion

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Suicide Gene Therapy

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Tumor Suppressor Gene Therapy

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Gene Modification

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Oncolytic Virotherapy

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Antisense and RNAi

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Immunotherapy Based Gene Therapy

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Others

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Cancer Gene Therapy Market, Indication Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Indication, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Breast Cancer

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Ovarian Cancer

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Liver Cancer

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Pancreatic Cancer

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Lung Cancer

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Prostate Cancer

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Others

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Cancer Gene Therapy Market, End-user Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By End-user, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Hospitals

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Oncology Institutes

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Research Institutes

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Biopharmaceutical Companies

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Diagnostic Centers

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. Other

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Cancer Gene Therapy Market, Region Segment Analysis

7.1. Overview

7.1.1. Global Market Revenue Share, By Region, 2025 & 2035

7.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

7.2. North America

7.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

7.2.2. North America Market Revenue, By Therapy Type, 2025-2035

7.2.3. North America Market Revenue, By Indication, 2025-2035

7.2.4. North America Market Revenue, By End-user, 2025-2035

7.2.5. The U.S.

7.2.5.1. U.S. Market Revenue, By Therapy Type, 2025-2035

7.2.5.2. U.S. Market Revenue, By Indication, 2025-2035

7.2.5.3. U.S. Market Revenue, By End-user, 2025-2035

7.2.6. Canada

7.2.6.1. Canada Market Revenue, By Therapy Type, 2025-2035

7.2.6.2. Canada Market Revenue, By Indication, 2025-2035

7.2.6.3. Canada Market Revenue, By End-user, 2025-2035

7.3. Europe

7.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

7.3.2. Europe Market Revenue, By Therapy Type, 2025-2035

7.3.3. Europe Market Revenue, By Indication, 2025-2035

7.3.4. Europe Market Revenue, By End-user, 2025-2035

7.3.5. Germany

7.3.5.1. Germany Market Revenue, By Therapy Type, 2025-2035

7.3.5.2. Germany Market Revenue, By Indication, 2025-2035

7.3.5.3. Germany Market Revenue, By End-user, 2025-2035

7.3.6. France

7.3.6.1. France Market Revenue, By Therapy Type, 2025-2035

7.3.6.2. France Market Revenue, By Indication, 2025-2035

7.3.6.3. France Market Revenue, By End-user, 2025-2035

7.3.7. U.K.

7.3.7.1. U.K. Market Revenue, By Therapy Type, 2025-2035

7.3.7.2. U.K. Market Revenue, By Indication, 2025-2035

7.3.7.3. U.K. Market Revenue, By End-user, 2025-2035

7.3.8. Italy

7.3.8.1. Italy Market Revenue, By Therapy Type, 2025-2035

7.3.8.2. Italy Market Revenue, By Indication, 2025-2035

7.3.8.3. Italy Market Revenue, By End-user, 2025-2035

7.3.9. Spain

7.3.9.1. Spain Market Revenue, By Therapy Type, 2025-2035

7.3.9.2. Spain Market Revenue, By Indication, 2025-2035

7.3.9.3. Spain Market Revenue, By End-user, 2025-2035

7.3.10. Rest of Europe

7.3.10.1. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

7.3.10.2. Rest of Europe Market Revenue, By Indication, 2025-2035

7.3.10.3. Rest of Europe Market Revenue, By End-user, 2025-2035

7.4. Asia Pacific

7.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

7.4.2. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

7.4.3. Asia Pacific Market Revenue, By Indication, 2025-2035

7.4.4. Asia Pacific Market Revenue, By End-user, 2025-2035

7.4.5. China

7.4.5.1. China Market Revenue, By Therapy Type, 2025-2035

7.4.5.2. China Market Revenue, By Indication, 2025-2035

7.4.5.3. China Market Revenue, By End-user, 2025-2035

7.4.6. Japan

7.4.6.1. Japan Market Revenue, By Therapy Type, 2025-2035

7.4.6.2. Japan Market Revenue, By Indication, 2025-2035

7.4.6.3. Japan Market Revenue, By End-user, 2025-2035

7.4.7. India

7.4.7.1. India Market Revenue, By Therapy Type, 2025-2035

7.4.7.2. India Market Revenue, By Indication, 2025-2035

7.4.7.3. India Market Revenue, By End-user, 2025-2035

7.4.8. Australia

7.4.8.1. Australia Market Revenue, By Therapy Type, 2025-2035

7.4.8.2. Australia Market Revenue, By Indication, 2025-2035

7.4.8.3. Australia Market Revenue, By End-user, 2025-2035

7.4.9. South Korea

7.4.9.1. South Korea Market Revenue, By Therapy Type, 2025-2035

7.4.9.2. South Korea Market Revenue, By Indication, 2025-2035

7.4.9.3. South Korea Market Revenue, By End-user, 2025-2035

7.4.10. Singapore

7.4.10.1. Singapore Market Revenue, By Therapy Type, 2025-2035

7.4.10.2. Singapore Market Revenue, By Indication, 2025-2035

7.4.10.3. Singapore Market Revenue, By End-user, 2025-2035

7.4.11. Rest of Asia Pacific

7.4.11.1. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

7.4.11.2. Rest of Asia Pacific Market Revenue, By Indication, 2025-2035

7.4.11.3. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

7.5. Latin America

7.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

7.5.2. Latin America Market Revenue, By Therapy Type, 2025-2035

7.5.3. Latin America Market Revenue, By Indication, 2025-2035

7.5.4. Latin America Market Revenue, By End-user, 2025-2035

7.5.5. Brazil

7.5.5.1. Brazil Market Revenue, By Therapy Type, 2025-2035

7.5.5.2. Brazil Market Revenue, By Indication, 2025-2035

7.5.5.3. Brazil Market Revenue, By End-user, 2025-2035

7.5.6. Argentina

7.5.6.1. Argentina Market Revenue, By Therapy Type, 2025-2035

7.5.6.2. Argentina Market Revenue, By Indication, 2025-2035

7.5.6.3. Argentina Market Revenue, By End-user, 2025-2035

7.5.7. Mexico

7.5.7.1. Mexico Market Revenue, By Therapy Type, 2025-2035

7.5.7.2. Mexico Market Revenue, By Indication, 2025-2035

7.5.7.3. Mexico Market Revenue, By End-user, 2025-2035

7.5.8. Rest of Latin America

7.5.8.1. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

7.5.8.2. Rest of Latin America Market Revenue, By Indication, 2025-2035

7.5.8.3. Rest of Latin America Market Revenue, By End-user, 2025-2035

7.6. MEA

7.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

7.6.2. MEA Market Revenue, By Therapy Type, 2025-2035

7.6.3. MEA Market Revenue, By Indication, 2025-2035

7.6.4. MEA Market Revenue, By End-user, 2025-2035

7.6.5. GCC Countries

7.6.5.1. GCC Countries Market Revenue, By Therapy Type, 2025-2035

7.6.5.2. GCC Countries Market Revenue, By Indication, 2025-2035

7.6.5.3. GCC Countries Market Revenue, By End-user, 2025-2035

7.6.6. South Africa

7.6.6.1. South Africa Market Revenue, By Therapy Type, 2025-2035

7.6.6.2. South Africa Market Revenue, By Indication, 2025-2035

7.6.6.3. South Africa Market Revenue, By End-user, 2025-2035

7.6.7. Rest of Middle-East & Africa

7.6.7.1. Rest of Middle-East & Africa Market Revenue, By Therapy Type, 2025-2035

7.6.7.2. Rest of Middle-East & Africa Market Revenue, By Indication, 2025-2035

7.6.7.3. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

8. Company Profile

8.1. Novartis International

8.1.1. Business Overview

8.1.2. Financial Performance

8.1.3. Therapy/Service Offerings

8.1.4. Strategies & recent developments

8.1.5. SWOT Analysis

8.2. Gilead Sciences, Inc

8.2.1. Business Overview

8.2.2. Financial Performance

8.2.3. Therapy/Service Offerings

8.2.4. Strategies & recent developments

8.2.5. SWOT Analysis

8.3. Bluebird Bio, Inc.

8.3.1. Business Overview

8.3.2. Financial Performance

8.3.3. Therapy/Service Offerings

8.3.4. Strategies & recent developments

8.3.5. SWOT Analysis

8.4. Bristol Myers Squibb Company

8.4.1. Business Overview

8.4.2. Financial Performance

8.4.3. Therapy/Service Offerings

8.4.4. Strategies & recent developments

8.4.5. SWOT Analysis

8.5. Genmab

8.5.1. Business Overview

8.5.2. Financial Performance

8.5.3. Therapy/Service Offerings

8.5.4. Strategies & recent developments

8.5.5. SWOT Analysis

8.6. Amgen Inc.

8.6.1. Business Overview

8.6.2. Financial Performance

8.6.3. Therapy/Service Offerings

8.6.4. Strategies & recent developments

8.6.5. SWOT Analysis

8.7. Spark Therapeutics, Inc.

8.7.1. Business Overview

8.7.2. Financial Performance

8.7.3. Therapy/Service Offerings

8.7.4. Strategies & recent developments

8.7.5. SWOT Analysis

8.8. Kite Pharma, Inc.

8.8.1. Business Overview

8.8.2. Financial Performance

8.8.3. Therapy/Service Offerings

8.8.4. Strategies & recent developments

8.8.5. SWOT Analysis

8.9. Zymeworks Inc.

8.9.1. Business Overview

8.9.2. Financial Performance

8.9.3. Therapy/Service Offerings

8.9.4. Strategies & recent developments

8.9.5. SWOT Analysis

8.10. Sangamo Therapeutics, Inc.

8.10.1. Business Overview

8.10.2. Financial Performance

8.10.3. Therapy/Service Offerings

8.10.4. Strategies & recent developments

8.10.5. SWOT Analysis

8.11. Autolus Therapeutics

8.11.1. Business Overview

8.11.2. Financial Performance

8.11.3. Therapy/Service Offerings

8.11.4. Strategies & recent developments

8.11.5. SWOT Analysis

8.12. Adaptimmune Therapeutics

8.12.1. Business Overview

8.12.2. Financial Performance

8.12.3. Therapy/Service Offerings

8.12.4. Strategies & recent developments

8.12.5. SWOT Analysis

8.13. Celyad Oncology

8.13.1. Business Overview

8.13.2. Financial Performance

8.13.3. Therapy/Service Offerings

8.13.4. Strategies & recent developments

8.13.5. SWOT Analysis

8.14. Cogent Biosciences

8.14.1. Business Overview

8.14.2. Financial Performance

8.14.3. Therapy/Service Offerings

8.14.4. Strategies & recent developments

8.14.5. SWOT Analysis

8.15. Merck

8.15.1. Business Overview

8.15.2. Financial Performance

8.15.3. Therapy/Service Offerings

8.15.4. Strategies & recent developments

8.15.5. SWOT Analysis

8.16. Intellia Therapeutics, Inc.

8.16.1. Business Overview

8.16.2. Financial Performance

8.16.3. Therapy/Service Offerings

8.16.4. Strategies & recent developments

8.16.5. SWOT Analysis

8.17. Crispr Therapeutics

8.17.1. Business Overview

8.17.2. Financial Performance

8.17.3. Therapy/Service Offerings

8.17.4. Strategies & recent developments

8.17.5. SWOT Analysis